Cargando…

The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study

SIMPLE SUMMARY: We evaluated the efficacy and safety of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKI) (ICI+TKI) in 51 patients with advanced or metastatic renal cell carcinoma (mRCC). In this study, 7.0 months was the median follow-up period. The overall survival rates at...

Descripción completa

Detalles Bibliográficos
Autores principales: Iinuma, Koji, Yamada, Toyohiro, Kameyama, Koji, Taniguchi, Tomoki, Kawada, Kei, Ishida, Takashi, Nagai, Shingo, Enomoto, Torai, Ueda, Shota, Takagi, Kimiaki, Kawase, Makoto, Takeuchi, Shinichi, Kawase, Kota, Kato, Daiki, Takai, Manabu, Nakane, Keita, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913458/
https://www.ncbi.nlm.nih.gov/pubmed/36765903
http://dx.doi.org/10.3390/cancers15030947
_version_ 1784885432353292288
author Iinuma, Koji
Yamada, Toyohiro
Kameyama, Koji
Taniguchi, Tomoki
Kawada, Kei
Ishida, Takashi
Nagai, Shingo
Enomoto, Torai
Ueda, Shota
Takagi, Kimiaki
Kawase, Makoto
Takeuchi, Shinichi
Kawase, Kota
Kato, Daiki
Takai, Manabu
Nakane, Keita
Koie, Takuya
author_facet Iinuma, Koji
Yamada, Toyohiro
Kameyama, Koji
Taniguchi, Tomoki
Kawada, Kei
Ishida, Takashi
Nagai, Shingo
Enomoto, Torai
Ueda, Shota
Takagi, Kimiaki
Kawase, Makoto
Takeuchi, Shinichi
Kawase, Kota
Kato, Daiki
Takai, Manabu
Nakane, Keita
Koie, Takuya
author_sort Iinuma, Koji
collection PubMed
description SIMPLE SUMMARY: We evaluated the efficacy and safety of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKI) (ICI+TKI) in 51 patients with advanced or metastatic renal cell carcinoma (mRCC). In this study, 7.0 months was the median follow-up period. The overall survival rates at 6, 12, and 18 months were 93.1%, 82.5%, and 68.8%, respectively. The median progression-free survival (PFS) was 19.0 months. The objective response and disease control rates were 68.6% and 88.2%, respectively. Patients aged ≥70 years and those with poor-risk mRCC had significantly poorer PFS than their counterparts. ICI+TKI-related adverse events occurred in 43 patients (84.3%) with any grade and in 22 patients (43.1%) with grade ≥3. Treatment selection with poor prognostic factors may be prudent, even though ICI+TKI is an efficacious and safe first-line treatment in patients with mRCC. ABSTRACT: We evaluated the efficacy and safety of combination therapy with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKI) as first-line therapy for patients diagnosed as having advanced or metastatic renal cell carcinoma (mRCC). We enrolled 51 patients to receive ICI+TKI therapy for mRCC at 9 Japanese institutions. The overall survival (OS) of the patients treated with ICI+TKI was the primary endpoint., and the secondary endpoints were progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Furthermore, we analyzed the clinical prognostic and predictive factors in patients with mRCC treated with ICI+TKI therapy. Seven months was the median follow-up period. The OS rates at 6, 12, and 18 months were 93.1, 82.5, and 68.8%, respectively. The median PFS for patients who received ICI+TKI was 19.0 months, ORR was 68.6%, and DCR was 88.2%. ICI+TKI-related adverse events occurred in 43 patients (84.3%) with any grade and in 22 patients (43.1%) with grade ≥3. Treatment selection with poor prognostic factors may be prudent, even though ICI+TKI is an efficacious and safe first-line treatment in patients with mRCC.
format Online
Article
Text
id pubmed-9913458
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99134582023-02-11 The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study Iinuma, Koji Yamada, Toyohiro Kameyama, Koji Taniguchi, Tomoki Kawada, Kei Ishida, Takashi Nagai, Shingo Enomoto, Torai Ueda, Shota Takagi, Kimiaki Kawase, Makoto Takeuchi, Shinichi Kawase, Kota Kato, Daiki Takai, Manabu Nakane, Keita Koie, Takuya Cancers (Basel) Article SIMPLE SUMMARY: We evaluated the efficacy and safety of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKI) (ICI+TKI) in 51 patients with advanced or metastatic renal cell carcinoma (mRCC). In this study, 7.0 months was the median follow-up period. The overall survival rates at 6, 12, and 18 months were 93.1%, 82.5%, and 68.8%, respectively. The median progression-free survival (PFS) was 19.0 months. The objective response and disease control rates were 68.6% and 88.2%, respectively. Patients aged ≥70 years and those with poor-risk mRCC had significantly poorer PFS than their counterparts. ICI+TKI-related adverse events occurred in 43 patients (84.3%) with any grade and in 22 patients (43.1%) with grade ≥3. Treatment selection with poor prognostic factors may be prudent, even though ICI+TKI is an efficacious and safe first-line treatment in patients with mRCC. ABSTRACT: We evaluated the efficacy and safety of combination therapy with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKI) as first-line therapy for patients diagnosed as having advanced or metastatic renal cell carcinoma (mRCC). We enrolled 51 patients to receive ICI+TKI therapy for mRCC at 9 Japanese institutions. The overall survival (OS) of the patients treated with ICI+TKI was the primary endpoint., and the secondary endpoints were progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Furthermore, we analyzed the clinical prognostic and predictive factors in patients with mRCC treated with ICI+TKI therapy. Seven months was the median follow-up period. The OS rates at 6, 12, and 18 months were 93.1, 82.5, and 68.8%, respectively. The median PFS for patients who received ICI+TKI was 19.0 months, ORR was 68.6%, and DCR was 88.2%. ICI+TKI-related adverse events occurred in 43 patients (84.3%) with any grade and in 22 patients (43.1%) with grade ≥3. Treatment selection with poor prognostic factors may be prudent, even though ICI+TKI is an efficacious and safe first-line treatment in patients with mRCC. MDPI 2023-02-02 /pmc/articles/PMC9913458/ /pubmed/36765903 http://dx.doi.org/10.3390/cancers15030947 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Iinuma, Koji
Yamada, Toyohiro
Kameyama, Koji
Taniguchi, Tomoki
Kawada, Kei
Ishida, Takashi
Nagai, Shingo
Enomoto, Torai
Ueda, Shota
Takagi, Kimiaki
Kawase, Makoto
Takeuchi, Shinichi
Kawase, Kota
Kato, Daiki
Takai, Manabu
Nakane, Keita
Koie, Takuya
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
title The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
title_full The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
title_fullStr The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
title_full_unstemmed The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
title_short The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
title_sort efficacy and safety of immune checkpoint inhibitor and tyrosine kinase inhibitor combination therapy for advanced or metastatic renal cell carcinoma: a multicenter retrospective real-world cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913458/
https://www.ncbi.nlm.nih.gov/pubmed/36765903
http://dx.doi.org/10.3390/cancers15030947
work_keys_str_mv AT iinumakoji theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT yamadatoyohiro theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT kameyamakoji theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT taniguchitomoki theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT kawadakei theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT ishidatakashi theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT nagaishingo theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT enomototorai theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT uedashota theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT takagikimiaki theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT kawasemakoto theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT takeuchishinichi theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT kawasekota theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT katodaiki theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT takaimanabu theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT nakanekeita theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT koietakuya theefficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT iinumakoji efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT yamadatoyohiro efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT kameyamakoji efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT taniguchitomoki efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT kawadakei efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT ishidatakashi efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT nagaishingo efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT enomototorai efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT uedashota efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT takagikimiaki efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT kawasemakoto efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT takeuchishinichi efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT kawasekota efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT katodaiki efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT takaimanabu efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT nakanekeita efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy
AT koietakuya efficacyandsafetyofimmunecheckpointinhibitorandtyrosinekinaseinhibitorcombinationtherapyforadvancedormetastaticrenalcellcarcinomaamulticenterretrospectiverealworldcohortstudy